Artia Global Partners LP — 13F Holdings & Portfolio
CIK 1937964 · latest 13F-HR filed 2026-05-15
Artia Global Partners LP manages $499.4M in 13F-reported U.S. long-equity assets across 50 reported positions as of its 2026-03-31 13F-HR filing. Its largest disclosed positions are INSM (20.59%), ABVX (13.39%), INSM (9.16%). Quarter over quarter (versus its 2025-12-31 filing) the fund opened 10 new positions, exited 12, added to 17, and trimmed 16.
AUM is the long-equity portion reported on Form 13F-HR. Excludes short positions, cash, foreign holdings, and non-13F assets. For informational purposes only — not investment advice.
$499.4M
Long-equity book
50
Distinct positions
2026-03-31
Filed 2026-05-15
+10 / −12 / ↑17 / ↓16
vs 2025-12-31
| Name | Title / Status | Ownership | Type |
|---|
Top Adds (vs prior quarter)
- DIANTHUS THERAPEUTICS INC$5.2M +61.8%
- REVOLUTION MEDICINES INC$3.9M +46.5%
- XENON PHARMACEUTICALS INC$2.0M +110.8%
- BELITE BIO INC$1.1M +38.5%
- QUEST DIAGNOSTICS INC$916.3K +12.9%
Top Trims
- ARGENX SE-$32.7M -60.1%
- SOLENO THERAPEUTICS INC-$22.4M -90.7%
- VIKING THERAPEUTICS INC-$19.4M -76.8%
- ELI LILLY & CO-$19.1M -35.2%
- INSMED INC-$15.9M -13.4%
New Positions
- ASTRAZENECA PLC$18.8M
- ALUMIS INC$7.2M
- MERCK & CO INC$5.6M
- TERNS PHARMACEUTICALS INC$5.5M
- JOHNSON & JOHNSON$5.5M
Exited Positions
- PROSHARES TR II$24.5M
- UNIQURE NV$24.5M
- ASTRAZENECA PLC$17.5M
- CIDARA THERAPEUTICS INC$15.6M
- ALNYLAM PHARMACEUTICALS INC$6.9M
Rows tagged Call or Put are options positions, not stock. Per SEC Form 13F-HR, Value shows the notional value of the underlying (shares covered × underlying price), not the option premium. Shares is the number of underlying shares covered (divide by 100 for contract count).
| # | Issuer | Symbol | CUSIP | Value | Weight | Shares | Type |
|---|---|---|---|---|---|---|---|
| 1 | INSMED INC | INSM | 457669307 | $102.8M | 20.59% | 628,712 | SH |
| 2 | ABIVAX SA | ABVX | 00370M103 | $66.9M | 13.39% | 600,747 | SH |
| 3 | INSMED INC Put | INSM | 457669307 | $45.7M | 9.16% | 279,700 | SH |
| 4 | ELI LILLY & CO | LLY | 532457108 | $35.2M | 7.04% | 38,220 | SH |
| 5 | TREVI THERAPEUTICS INC | TRVI | 89532M101 | $24.0M | 4.81% | 2,013,602 | SH |
| 6 | ARGENX SE | ARGX | 04016X101 | $21.7M | 4.35% | 29,739 | SH |
| 7 | ASTRAZENECA PLC | AZN | G0593M107 | $18.8M | 3.77% | 95,376 | SH |
| 8 | NEWAMSTERDAM PHARMA COMPANY | NAMS | N62509109 | $16.1M | 3.23% | 503,936 | SH |
| 9 | DIANTHUS THERAPEUTICS INC | DNTH | 252828108 | $13.7M | 2.74% | 162,990 | SH |
| 10 | REVOLUTION MEDICINES INC | RVMD | 76155X100 | $12.2M | 2.43% | 124,990 | SH |
| 11 | IONIS PHARMACEUTICALS INC | IONS | 462222100 | $10.8M | 2.17% | 144,376 | SH |
| 12 | MODERNA INC Call | MRNA | 60770K107 | $10.2M | 2.03% | 200,000 | SH |
| 13 | EYEPOINT INC | EYPT | 30233G209 | $9.9M | 1.98% | 767,098 | SH |
| 14 | QUEST DIAGNOSTICS INC | DGX | 74834L100 | $8.0M | 1.60% | 40,817 | SH |
| 15 | ALUMIS INC | ALMS | 022307102 | $7.2M | 1.43% | 325,046 | SH |
| 16 | VIKING THERAPEUTICS INC | VKTX | 92686J106 | $5.9M | 1.18% | 180,731 | SH |
| 17 | MERCK & CO INC | MRK | 58933Y105 | $5.6M | 1.12% | 46,700 | SH |
| 18 | TERNS PHARMACEUTICALS INC | TERN | 880881107 | $5.5M | 1.11% | 104,800 | SH |
| 19 | JOHNSON & JOHNSON | JNJ | 478160104 | $5.5M | 1.11% | 22,600 | SH |
| 20 | SIONNA THERAPEUTICS INC | SION | 829401108 | $4.8M | 0.96% | 119,741 | SH |
| 21 | SCHOLAR ROCK HLDG CORP | SRRK | 80706P103 | $4.7M | 0.95% | 96,285 | SH |
| 22 | RAPPORT THERAPEUTICS INC | RAPP | 75383L102 | $4.3M | 0.87% | 138,508 | SH |
| 23 | ASCENDIS PHARMA A/S | ASND | 04351P101 | $4.1M | 0.81% | 17,740 | SH |
| 24 | BELITE BIO INC | BLTE | 07782B104 | $4.0M | 0.80% | 24,989 | SH |
| 25 | XENON PHARMACEUTICALS INC | XENE | 98420N105 | $3.8M | 0.76% | 65,000 | SH |
| 26 | MINERALYS THERAPEUTICS INC | MLYS | 603170101 | $3.7M | 0.75% | 137,800 | SH |
| 27 | ROIVANT SCIENCES LTD | ROIV | G76279101 | $3.6M | 0.72% | 129,800 | SH |
| 28 | PALISADE BIO INC | PALI | 696389402 | $3.5M | 0.70% | 1,992,367 | SH |
| 29 | BIOGEN INC | BIIB | 09062X103 | $3.4M | 0.68% | 18,437 | SH |
| 30 | PROKIDNEY CORP | PROK | 74291D104 | $3.2M | 0.65% | 1,806,939 | SH |
| 31 | ABBVIE INC | ABBV | 00287Y109 | $3.2M | 0.63% | 14,500 | SH |
| 32 | UNITED THERAPEUTICS CORP DEL | UTHR | 91307C102 | $3.0M | 0.59% | 5,000 | SH |
| 33 | BRIGHT MINDS BIOSCIENCES INC | DRUG | 10919W405 | $2.8M | 0.56% | 38,407 | SH |
| 34 | PROTAGONIST THERAPEUTICS INC | PTGX | 74366E102 | $2.4M | 0.48% | 22,931 | SH |
| 35 | SOLENO THERAPEUTICS INC | SLNO | 834203309 | $2.3M | 0.46% | 68,490 | SH |
| 36 | BRIGHTSPRING HEALTH SVCS INC | BTSG | 10950A106 | $2.3M | 0.46% | 53,800 | SH |
| 37 | TRAVERE THERAPEUTICS INC | TVTX | 89422G107 | $2.1M | 0.42% | 70,700 | SH |
| 38 | EDGEWISE THERAPEUTICS INC | EWTX | 28036F105 | $2.1M | 0.41% | 65,500 | SH |
| 39 | CELCUITY INC | CELC | 15102K100 | $1.8M | 0.36% | 15,576 | SH |
| 40 | BRIDGEBIO PHARMA INC | BBIO | 10806X102 | $1.5M | 0.30% | 20,400 | SH |
| 41 | KINIKSA PHARMACEUTICALS INTL | KNSA | G52694109 | $1.4M | 0.28% | 29,200 | SH |
| 42 | CYTOKINETICS INC | CYTK | 23282W605 | $1.1M | 0.22% | 16,300 | SH |
| 43 | ENLIVEN THERAPEUTICS INC | ELVN | 29337E102 | $819.3K | 0.16% | 20,900 | SH |
| 44 | PRAXIS PRECISION MEDICINES I | PRAX | 74006W207 | $805.5K | 0.16% | 2,500 | SH |
| 45 | TENAX THERAPEUTICS INC | TENX | 88032L605 | $672.9K | 0.13% | 42,080 | SH |
| 46 | KODIAK SCIENCES INC | KOD | 50015M109 | $648.8K | 0.13% | 17,019 | SH |
| 47 | NUVALENT INC | NUVL | 670703107 | $502.0K | 0.10% | 4,900 | SH |
| 48 | APOGEE THERAPEUTICS INC | APGE | 03770N101 | $495.4K | 0.10% | 5,886 | SH |
| 49 | AVALO THERAPEUTICS INC | AVTX | 05338F306 | $432.5K | 0.09% | 28,970 | SH |
| 50 | PEPGEN INC | PEPG | 713317105 | $363.4K | 0.07% | 205,324 | SH |
| Period | Filed | AUM | Holdings | Accession |
|---|---|---|---|---|
| 2026-03-31 | 2026-05-15 | $499.4M | 50 | 0001937964-26-000007 |
| 2025-12-31 | 2026-02-17 | $705.8M | 55 | 0001937964-26-000002 |
| 2025-09-30 | 2025-11-14 | $630.9M | 51 | 0001937964-25-000009 |